NHS still 'long way' from routine Alzheimer's testing to benefit from groundbreaking drugs UK to decide if treatments found to slow early signs of Alzheimer's are safe READ MORE: How to drastically slash your odds of getting Alzheimer's By Kate Pickles Health Editor For The Daily Mail Published: 23:30, 11 June 2024 | Updated: 23:30, 11 June 2024 e-mail View comments The NHS is ‘a long way’ from being able to provide a new class of Alzheimer’s drugs to patients should they get approval, research suggests. The UK is on the cusp of deciding whether the first treatments found to slow down the early signs of disease are safe and effective. Regulators are expected to rule on lecanemab in the coming weeks and donanemab later this year, with both treatments now given the go-ahead in the US.
Approval would mark a major change in treatment because they target one of the known causes of Alzheimer's , rather than just helping to relieve symptoms. But experts have warned the lack of proper testing means the NHS faces being swamped with patients wrongly assumed to have the disease. UK is on the cusp of deciding whether the first treatments found to slow down the early signs of disease are safe and effective Regulators are expected to rule on the Alzheimer's drug lecanemab (pictured) in the coming weeks and another donanemab later this year They said there is a ‘clear and urgent’ need to improve NHS screening to work out who may benefit from new Alzheimer's drugs.
Researchers incl.
